Chlamydia trachomatis is a common sexually transmitted infection that can cause pelvic inflammatory disease, infertility, and other reproductive complications when it spreads to the upper genital tract. Currently, ascension into the uterus and endometrium
Machine Learning Enables Gas Sensors to Detect Antimicrobial Resistance at Point-of-Care
Fast and accurate diagnosis is critical to improving patient care and combating the global threat of antimicrobial resistance (AMR). Traditional diagnostic methods for infections, such as gas chromatography-mass spectrometry and proton transfer reaction–
mass spectrometry, while effective, are expensive, technically demanding, and unsuitable for pointof-care settings. Interpreting volatile organic compounds (VOCs)— the unique chemical signatures emitted by microbes and infected tissues—can be challenging due
Saliva-Based Cancer Detection Technique
Early detection of cancer is crucial for effective treatment and improved outcomes, yet current diagnostic methods often involve invasive procedures and complex sample preparation. These barriers limit accessibility and delay diagnosis, particularly in low-resource settings. For example, detecting tumor-specific mutations typically requires blood samples or tissue biopsies,
DLM 2025, the world’s largest in vitro diagnostics gathering, was held in Chicago on Ju ly 27-31. The event fea tured over 800 industry exhibitors from around the world that showcased cutting-edge innovations in the various areas of Laboratory Medicine.
Handheld Microfluidic Device Delivers HbA1c Results in Minutes
For people living with diabetes, A1C testing is a key part of managing health, as it shows average blood sugar levels over the past two to three months. Despite its importance, many people do not test their A1C as often as
Paper-Based Device Detects Immune Defects in 10 Minutes
Patients with hidden immune defects are especially vulnerable to severe and persistent infections, often due to autoantibodies that block interferon-gamma (IFN-γ), a key molecule in immune defense. These autoantibodies can go undetected for
extended periods, making diagnosis difficult and delaying critical treatment. Traditional testing methods can be slow, expensive, and insensitive to trace levels of harmful antibodies, especially in the early stages of illness. Now, researchers have developed a
DCont’d on page 10
Uric Acid Testing Without Blood Draw
iagnosing elevated uric acid (UA) levels—an important indicator for conditions like gout, chronic kidney disease, and metabolic syndrome—typically requires blood draws, lab equipment, trained technicians, and expensive reagents. These conventional diagnostic methods are invasive, time-consuming, and inaccessible for daily monitoring or use in remote settings. Patients
Cont’d on page 12
Cont’d on page 9
Cont’d on page 2
New Markers Predict Risk of Chlamydia Infection
Cont’d from cover can only be confirmed through an invasive endometrial biopsy. Researchers have now identified biological markers that may pave the way for new diagnostics to predict a woman’s risk of severe infection without the need for such procedures.
A collaborative team from North Carolina State University (Raleigh, NC, USA; (Raleigh, NC, USA; www.ncsu.edu) and the UNC School of Medicine (Chapel Hill, NC, USA; med.unc.edu) analyzed cervicovaginal microbiome (CVM) samples from 246 women in a high-risk cohort for chlamydia. Using 16S ribosomal RNA (rRNA) gene-based high-throughput amplicon sequencing, they tagged and
quantified bacteria present in the samples. Participants were classified into three groups—CT negative, CT positive, and CT ascended—to assess differences in microbiome composition.
The sequencing analysis revealed that higher amounts of certain bacterial species, such as Hemophilus haemolyticus, Sutterella stercoricanis, and Actinobaculum massiliense, were predictive of ascended infections. These microbes also correlated with seven cytokines previously linked to chlamydia spread. Notably, the study found that the bacterial load of chlamydia itself was the strongest predictor of ascension.
The findings, published in Infection and Immunity, indicate that specific microbial and immune profiles could be developed into biomarkers to identify women at high risk for upper genital tract infection. Such diagnostics could enable earlier intervention, potentially preventing severe reproductive outcomes. Future studies will focus on understanding how these microbes influence immune responses to control chlamydia levels and disease progres-
“We knew that some bacterial species make a woman more susceptible to CT infection, while ‘good’ bacteria such as lactobacillus seem to make it harder to become infected,” said Catherine O’Connell, professor of pediatrics, UNC School of Medicine, and co-project leader. “This work shows that other bacteria present may be keeping host immunity alert and responsive, making it harder for infecting chlamydia to grow abundantly. It shows that there is potential for developing biomarkers to identify women at high risk for ascended CT.”
Image: New diagnostics could predict a woman’s risk of a common sexually transmitted infection (Photo courtesy of 123RF)
Fast + Reliable Women’s Health Testing Solutions To Meet Your Needs
Your patients depend on you to provide the best care possible and find solutions for the most uncomfortable situations.
Our high-quality, women’s health rapid tests designed to be accurate and easy to use so you can get results fast. We help you deliver answers and treatment plans getting your patients on the road to recovery fast.
We make diagnostics that matter because we believe each test represents the health and well-being of a real person.
Learn more about our tests for Trichomonas and Bacterial Vaginosis by visiting us online at sekisuidiagnostics.com/womens-health.
ADLM 2025 Review: Latest Advances in Clinical Diagnostics
The Association for Diagnostics & Laboratory Medicine (ADLM, formerly AACC, Washington, DC, USA; www.myadlm.org) welcomed thousands of laboratory experts to ADLM 2025 (formerly the AACC Annual Scientific Meeting & Clinical Lab Expo) in Chicago, Illinois from July 2731. The meeting showcased advancements in clinical laboratory testing that improve the ability of healthcare professionals to diagnose patients and make sure that patients get effective medical treatment.
Nearly 16,500 labora tory medicine professionals registered for ADLM 2025 which offered five days packed with opportunities to learn about exciting sci ence. At the ADLM 2025 Clinical Lab Expo, nearly 800 exhibitors filled the show floor covering an expanse of 240,402 net square feet at the McCormick Place Convention Center in Chicago. This dynamic exhibit featured cutting-edge tests from all laboratory medicine disciplines, including artificial intelligence (AI), clinical microbiology, molecular diagnostics, automation, point-of-care testing, mass spectrometry, and much more.
truly valuable tools from those with limited or misleading benefits, while the second explored how to leverage data science to quantify the value of laboratory medicine testing. The symposium brought together many different perspectives on data science for all laboratories, not just one specific kind of laboratory, with participants coming from academia, community hospitals, and industry.
As part of ADLM’s Disruptive Technology Award competition, biotech innovators presented novel technologies that could help more patients get accurate diagnoses.
Graham
Hernán
Argentina
Bernard Gouget France
Maurizio Ferrari Italy
Tahir S. Pillay South Africa
Andreas Rothstein Colombia
Praveen Sharma India
Rosa I. Sierra-Amor Mexico
Peter Wilding United States
Andrew Wootton United Kingdom
Rarity Bioscience (Uppsala, Sweden; raritybioscience.com ) won the competition with its superRCA technology – an ultrasensitive test for detecting rare cancercausing mutations in blood or tissue samples. This technology allows molecular analysis via standard flow cytometry, which is already widely available in hematology and pathology labs. By leveraging existing infrastructure, superRCA enables the seamless adoption of advanced molecular diagnostics without additional capital investment.
The major highlights of the meeting included plenary talks presented by luminaries in the field. Plenaries address timely topics applicable to all laboratorians and span the breadth of research and medicine. Plenary sessions explored urgent problems related to clinical AI integration, fake medical news, and the pervasiveness of plastics, as well as tapping into the promise of genomics and microbiome medicine for personalized healthcare.
For the second year in a row, a Data Science Symposium was added to the meeting program. The day was packed with impactful “lightning” talks, where experts spoke for 10 to 15 minutes about their current work in data science, alongside two panel presentations. The first panel examined the practical and ethical challenges of implementing AI in diagnostics, including how to distinguish
ACES Diagnostics (New Orleans, LA, USA; www.acesdiagnostics.com) introduced a new test that utilizes AI to significantly enhance Lyme disease detection. The ACES team developed a single-panel test that screens for 10 different proteins (antigens), streamlining diagnosis compared to the traditional method that may require up to four separate tests. After validation on clinical samples, they integrated machine-learning to recognize distinct immune response patterns. The final algorithm performed robustly across all stages, detecting over 90% of early-stage cases – a sharp contrast to the 27% accuracy rate seen with the standard two-tier approach.
Amplified Sciences (West Lafayette, IN, USA; www.amplifiedsciences.com) presented new clinical validation data highlighting
Cont’d on page 5
LabMedica lnternational is published eight times a year and is circuIated worldwide (outside the USA and Canada) without charge and by written request, to clinical laboratory specialists and administrators, and other qualified professionals allied to the field.
To all others: Paid Subscription is available for a two-year subscription charge of US$120. Single copy price is US$20. Mail your paid subscription order accompanied with payment to Globetech Media, P.O.B. 800222, Miami, FL 33280-0222.
For change of address or questions on your subscription, write to: LabMedica lnternational, Circulation Services at above address; or visit: www.LinkXpress.com
recent findings related to the stratification of pancreatic cystic lesions (PCL), a known precursor lesion for pancreatic cancer that presents a complex and increasingly common clinical challenge. The work builds on PanCystPro, its CLIA-cleared assay that is designed to assist clinicians in the risk stratification of patients diagnosed with PCL by distinguishing between mucinous and non-mucinous cysts using comparatively less fluid. This test will address the need of gastroenterologists, pancreatic biliary surgeons, and other clinicians for better diagnostic tests to manage patients diagnosed with pancreatic cysts.
Bio-Rad Laboratories (Hercules, CA, USA; www.bio-rad.com) offered live demonstrations and personalized walkthroughs of its QC solutions, transfusion medicine automation, autoimmune and infectious disease multiplexing, and HPLC testing platforms. Among its QC solutions highlighted at the show was Unity QC Data Management Solution that is designed to optimize QC laboratory practices and streamline workflows. Bio-Rad also highlighted the IH 500 NEXT System medium-throughput blood typing instrument, alongside the BioPlex 2200 fully automated, random access multiplex system. Visitors to the company’s booth also experienced the D-100 Hemoglobin Testing System which simplifies high-throughput A1c testing without sacrificing the high-quality results that are critical to patient care.
Jiangsu Bioperfectus Technologies (Shanghai, China; www.bioper fectus.com) showcased the SSPGL01A fully automated NGS library preparation system that provides a flexible, fully-automated solution to standardized NGS library preparation. Bioperfectus also highlighted SAW-48, its seamless sample-to-PCR solution that integrates cutting-edge mechanical, electronic, and software technologies. Additionally, Bioperfectus presented its rapid diagnostic solutions for key infectious threats such as respiratory infections, Mpox (monkeypox) and vector-borne diseases.
Cytovale (San Francisco, CA, USA; www.cytovale.com) presented new multicenter study data which revealed that targeted sepsis testing at triage in the ED may be key to preserving inpatient bed capacity for the most severe patients. Cytovale’s IntelliSep is a rapid diagnostic tool for sepsis that is supporting emergency clinicians in making more confident decisions by quickly assessing patients’ sepsis risk. The study revealed that using IntelliSep’s rapid host-response test led to a 56% relative increase in discharges from the ED among patients identified as low risk, while simultaneously reducing the use of inpatient beds—without causing a rise in return visits. By applying this risk assessment tool early during triage, clinicians were able to avoid unnecessary admissions and discharge patients more confidently.
Lp-PLA2 FS
Closing the Gap of Cardiovascular Risk Assessment
Diatron (Budapest, Hungary; www.stratec.com ) presented its
• Uncover hidden cardiac risk independent of traditional lipid levels
• Target vascular inflammation specific to atherosclerosis
• Complement imaging by revealing small, vulnerable plaques
• Utilize liquid-stable, ready-to-use reagents for fully automated analyzers
newly launched clinical chemistry analyzer, the P780, which is designed to provide outstanding performance and maximum efficiency, without compromising affordability, to meet the growing demands of modern laboratories. Diatron also showcased Aquila, its innovative
Cont’d on page 6
PORTABLE URINE ANALYZER URITEST MEDICAL ELECTRONIC
The UC-32B is a portable urine analyzer for rapid and precise urine analysis in clinical and veterinary settings. It delivers accurate results for up to 14 parameters, including creatinine, microalbumin, calcium,
and revolutionary 3-part differential hematology analyzer that can be used in any testing location and application where high quality CBC results are desired. Additionally, Diatron also highlighted its Aquarius 3 hematology analyzer that combines technology and simplicity to give all the required information, reducing the unnecessary steps to a minimum whilst maintaining the balance between cost and benefit for patients and users alike.
EKF Diagnostics (Cardiff, Wales, UK; www.ekfdiagnostics.com) showcased the DiaSpect Tm hand-held hemoglobin analyzer and the Hemo Control hemoglobin testing and hematocrit estimation device, which are designed to provide quick, reliable, and accurate results in diverse healthcare settings. EKF also presented the STAT-Site WB, which provides rapid and precise quantitative results for β-ketone and glucose measurements, and the Beta-Hydroxybutyrate LiquiColor reagent, a quantitative FDA-cleared test for detecting ketones and monitoring diabetic ketoacidosis.
Greiner Bio-One (Monroe NC, USA; www.gbo.com) launched the new VACUETTE Urine STB urinalysis tube that offers room-temp sample stability up to 72 hours. The tube offers a standardized solution to ensure stability of urinalysis samples by ensuring sample integrity. The all-new VACUETTE Urine STB Tube stabilizes key parameters for dipstick testing, clinical chemistry and urine sediment analysis for up to 72 hours without refrigeration.
InBios International (Seattle, WA, USA; www.inbios.com) introduced Lyme Detect Multiplex ELISA, its innovative array-based immunoassay in a traditional ELISA plate format that incorporates an automated software package to analyze, quantify and – using machine learning interpretations – classify specimens. This novel approach is designed to significantly improve workflow and acute stage sensitivity for the diagnosis of Lyme disease. The test made its debut at the ADLM Conference, where James Needham, PhD, InBios’ Director of Product Development, gave a talk called “AI-Powered Lyme Diagnostics: The Future is Multiplexed” about the new diagnostic at the conference.
MeMed (Haifa, Israel; www.me-med.com) and Beckman Coulter (Brea, CA, USA; www.beckmancoulter.com) hosted a special breakfast symposium, where the companies unpacked the real-world impact of the MeMed BV test in clinical practice. MeMed BV is the first FDA-cleared host-immune response test for accurately distinguishing between bacterial and viral infections in 15 minutes. MeMed also
The Quidel Triage cardiac panel is a rapid, point-ofcare fluorescence immunoassay designed to determine the level of creatine kinase MB (CK-MB), myoglobin and troponin I in EDTA anticoagulated whole blood or plasma specimens.
announced the completion of its multi-year development of MeMed BV Flex, an innovative, next-generation test designed to expand the reach of MeMed BV into decentralized, CLIA-waived settings. The test enables accurate differentiation between bacterial and viral infections in just 15 minutes using only a few drops of capillary blood from a finger prick.
Mindray (Shenzhen, China; www.mindray.com) returned to ADLM After five years with a focus on its MT 8000 Intelligent TLA Solution designed for streamlined, automated laboratory operations. Mindray also highlighted its ALL IN ONE Hematology Solution which brings greater efficiency to hematology testing with simplified workflows and ease of operation. Additionally, Mindray presented the FA-N60 nextgeneration scalable blood culture system that features real-time blood volume monitoring, an intelligent satellite information transmission system, and newly designed culture bottles. Mindray also won the Academy Distinguished Abstracts Awards for its groundbreaking research in cardiac troponin testing.
Puritan Medical Products (Guilford, ME, USA; www. puritanmedical.com) showcased its latest specimen collection and transport solutions for clinical and diagnostic laboratories. At its booth, the company showcased its flocked swab portfolio, including the patented HydraFlock®, engineered with intricate, multi-length fibers for rapid absorption and efficient release of biological specimens. Puritan also highlighted its transport media systems, such as Puritan® UniTranz-RT® for the collection and preservation of viruses, chlamydia, mycoplasma, and ureaplasma, and Puritan® Opti-Swab® with Liquid Amies for aerobic, anaerobic, and fastidious bacteria.
QuidelOrtho (San Diego, CA, USA; www.quidelortho.com) demonstrated its VITROS Automation Solutions which combined with VITROS chemistry and immunoassay systems can deliver high-quality results, faster than VITROS systems alone. QuidelOrtho also showcased the VITROS XT 7600 Integrated system which offers a full clinical chemistry and immunoassay menu in one easyto-use system that delivers industry-leading uptime. Additionally, QuidelOrtho highlighted the Ortho Vision Max Swift automated immunohematology system which can automate more than 99% of blood typing and antibody screening, without compromising turnaround time.
Scopio Labs (Parsippany, NJ, USA; www.scopiolabs.com) unveiled its groundbreaking Complete Blood Morphology (CBM) analyzer, bringing unprecedented scale, efficiency and standardization to hematology through autonomous morphology analysis and reporting, one of the last remaining manual processes in diagnostics. CBM is built
Cont’d on page 7
ADLM 2025 Review
Cont’d from page 5
on top of Scopio’s proprietary Full-Field technology, leveraging advanced computational imaging and AI-powered analysis to transform current PBS review workflow into an autonomous, standardized, and clinically relevant process, analyzing 10x more cells than the current standard of care in blood cell morphology.
Seegene (Seoul, South Korea; www.seegene.com) unveiled its fully automated PCR testing system, CURECA, and its data analytics platform, STAgora. CURECA is the world’s first system to fully automate the entire PCR testing process – from sample storage and pre-treatment to nucleic acid extraction, amplification, and result analysis – without any human intervention. On the other hand, STAgora, Seegene’s new statistical platform collects and analyzes real-time PCR diagnostic data to support clinical decision-making. By aggregating test data uploaded from hospitals around the world, the platform provides integrated insights into regional infection trends, hospital-level positivity rates, and patterns of co-infection.
Siemens Healthineers (Forchheim, Germany; www.siemenshealthineers.com) introduced FlexLab X1, its next-generation total lab automation solution which offers unrivaled multidisciplinary consolidation, intelligent software, and the highest throughput on the market. Siemens also unveiled the new Atellica DT 250 Drug Testing Analyzer, which combines trusted, proven Syva EMIT technologies with the practicality and reliability labs need to meet the high-stakes demands of today’s drug-testing facilities. This small benchtop system offers the throughput and onboard sample capacity previously only available in larger, floor-standing models.
Thermo Fisher Scientific (Waltham, MA; USA; www.thermofisher. com) launched two new solutions, LabLink360 and Thermo Scientific MAS Max quality controls, designed to support quality control assurance and streamline workflows in clinical laboratories. The company also showcased its rapid next-generation sequencing (NGS) technology, recently approved by the U.S. FDA, the Oncomine Dx Express Test on the Ion Torrent Genexus Dx Integrated Sequencer, for use as a companion diagnostic for Dizal’s ZEGFROVY (sunvozertinib) and for tumor profiling applications. Additionally, Thermo Fisher highlighted its PreClara Ratio, cleared in 2023 and previously known as B·R·A·H·M·S sFlt-1/PlGF KRYPTOR Test System, which offers clarity in assessing the risk of developing preeclampsia with severe features in hospitalized pregnant women within two weeks of testing.
Tianlong Science and Technology (Shaanxi, China; www. tlgenetech.cn) and Shanghai Kehua Biotech (KHB, Shanghai, China; www.skhb.com) jointly showcased a comprehensive portfolio of advanced solutions. Visitors to the booth experienced the KHB Polaris V150 desktop fully automatic chemiluminescence immunoassay analyzer from the KHB Polaris series. Also on display was the Tianlong Panall 8000 open system that enables laboratories to program userdefined PCR analysis protocols. Tianlong also showcased the Gentier X3 Series Real-Time PCR system and Gentier Mini+ 4 channels Portable Real-Time PCR system. Additionally, Tianlong highlighted the Biolum Portable ATP Monitoring System Pro, its new-generation hygiene monitoring system featuring an innovative design that makes the instrument a smartphone in the hand.
Werfen (Barcelona, Spain; www.werfen.com) unveiled the next generation of its ACL TOP hemostasis testing systems which optimize workflow with a powerful combination of quality and efficiency, and connectivity across an entire laboratory network. Werfen also announced the expansion of its award-winning Gem Premier 7000 with iQM3 to Europe, following its strong clinical adoption in North America. The GEM Premier 7000 is the first blood gas testing system to integrate hemolysis detection at the point of care, addressing the most common preanalytical error in blood gas testing.
The ADLM Annual Meeting & Clinical Lab Expo 2026 will take place in Anaheim, California, from July 26-30, 2026.
PurSafe Plus® Collection & Transpor t System
COMING SOON FROM PURITAN with patented swabs
Safe Plus® Collection & Transport System, for the collection, inactivation and upper respiratory tract specimens containing SARS-CoV-2, featuring patented locked swabs.
R SO N oth # 1 12 9
L EA R N M O R E ONLIN E info.puritanmedproducts.com/pursafe-plus
RESPIRATORY SYNCYTIAL VIRUS TEST
SEKISUI DIAGNOSTICS
The OSOM® RSV Test is a CLIA-waived, point-of-care test designed to detect RSV using a painless anterior nasal swab, in just 15 minutes. It is suitable for both children aged 6 months to 6 years and adults aged
Precision Tool Predicts Immunotherapy Treatment Failure in Melanoma Patients
Melanoma, though accounting for only about 4% of skin tumors, is the deadliest form of skin cancer due to its high potential to metastasize. While immunotherapy, especially PD-1 protein blockade, has revolutionized treatment for advanced melanoma, 40% to 60% of patients do not respond effectively. This not only exposes them to significant side effects but also imposes a heavy financial burden. In countries like Brazil, this poses serious challenges to healthcare systems, creating a pressing need to identify which patients will benefit from immunotherapy and to avoid unnecessary costs and treatment failures. Researchers have now developed a precision tool that can predict immunotherapy treatment failure, with the potential to personalize therapies and reduce healthcare costs.
In the study led by the Molecular Oncology Research Center at Hospital de Amor (Barretos, Brazil; www.hospitaldeamor.com.br), researchers analyzed tumor samples from 35 patients with advanced melanoma treated with anti-PD-1 immunotherapy between 2016 and 2021. The team cross-referenced these samples with a panel of 579 genes related to immune system function, ultimately identifying four genes — CD24, NFIL3, FN1, and KLRK1 — whose increased expression correlated with treatment resistance. These genes are involved in immune evasion and suppression of the inflammatory response. For instance, CD24 acts as an immune checkpoint, while FN1 supports tumor growth, KLRK1 loses its immune activation function when dysregulated, and NFIL3 contributes to tumor escape. The study utilized NanoString technology, a cost-effective and accessible genetic analysis platform suitable for clinical use in resource-limited settings. Notably, the genetic signature also showed predictive power for early-stage melanoma patients, indicating its usefulness from the beginning of treatment planning.
The findings, published in the Journal of Molecular Medicine, were validated against two international patient cohorts, where the gene expression signature consistently predicted both treatment response and clinical outcomes. According to the results, patients with high expression of the four genes were 230 times more likely to fail immunotherapy, with only 5.9% surviving after five years compared to 48.1% in those with low gene expression. The research team is now working on patenting a genetic panel based on this signature, with plans to develop a commercial tool that can guide treatment decisions before initiating immunotherapy. Despite the study’s small size and retrospective nature, the findings mark a significant advancement in personalized oncology in Brazil. The next step involves conducting larger studies to define a gene expression threshold that can reliably predict treatment failure.
CHEMISTRY ANALYZER BECKMAN COULTER
The DxC 500 AU is a fully automated, random-access clinical chemistry analyzer designed for small to mid-volume labs. It delivers up to 800 photometric tests per hour with integrated ion-selective electrodes (ISEs).
Wireless Sweat Patch Could Be Used as Diagnostic Test for Cystic Fibrosis
Cystic fibrosis (CF) is a genetic disease that causes excessive mucus to accumulate in the lungs, impairs digestion, and can affect multiple organs. More than 40,000 children and adults in the U.S. currently live with the disease, which is progressive and often results in early mortality. While treatments exist to improve quality of life, optimizing the use of new drugs outside clinical settings remains a challenge. A new wearable device now offers a way to monitor CF patients more effectively and provide real-time insights into treatment efficacy.
Developed by researchers from Northwestern Medicine (Chicago, IL, USA; www.nm.org) in collaboration with spinout company Epicore Biosystems (Cambridge, MA, USA; www.epicorebiosystems.com), the CF patch is a wireless sticker-like device that measures biomarkers in sweat. The patch is worn on the wrist and includes two channels: one for measuring sweat volume and another for measuring sweat chloride, the key diagnostic marker of CF. Physicians capture an image of the patch using a smartphone or tablet, and color changes are analyzed to provide data comparable in accuracy to laboratory-based testing.
In a study published in the Proceedings of the National Academy of Sciences, researchers evaluated the patch’s accuracy against the gold-standard chloride sweat test. To test feasibility, 20 adults with cystic fibrosis and seven healthy controls completed both a clinic-based chloride sweat test and five remote exercise sessions over 14 days while wearing the device. Researchers found that the CF patch measured sweat chloride as effectively as tests done in specialized laboratories.
These findings demonstrate that the wearable microfluidic sweat patch can deliver accurate, remote monitoring of sweat chloride in individuals with CF. Such technology could optimize the use of CFTR (cystic fibrosis transmembrane conductance regulator) modulator drugs, which improve protein function and disease trajectory, by offering consistent data on treatment effectiveness. The next phase will assess whether the device can guide clinical decision-making more directly in patient care.
Going forward, the patch could expand CF screening and monitoring in rural and under-resourced areas with limited access to diagnostic labs. By providing reliable results outside clinical environments, the device has the potential to expedite diagnosis and improve long-term disease management.
“We wanted to see how accurate our CF patch was relative to the gold standard, whether we could do it remotely at home, and then also see how consistent the sweat chloride is in response to the medications (i.e., CFTR modulators),” said Manu Jain, MD, senior author of the study. “Potentially this could be used as a screening or diagnostic test in parts of the country where sweat testing is not readily available and could expedite the diagnosis of cystic fibrosis.”
Machine Learning Enables Gas Sensors to Detect Antimicrobial Resistance at Point-of-Care
to their complexity and overlap. Moreover, these VOC signals are often influenced by environmental variables, which adds to diagnostic inaccuracy. A report published in Cell Biomaterials explores the use of sensor systems combined with advanced computational models to detect and classify microbial VOCs with high precision.
This report by researchers at ETH Zurich (Zurich, Switzerland; ethz.chl) presents a promising approach that combines gas sensors and machine learning for real-time infection diagnosis. The report explores how gas sensors made from nanostructured metal oxides, conductive polymers, and hybrid composites could offer a compact, affordable, and practical solution for detecting VOCs. These sensors measure changes in electrical resistance or conductance when exposed to microbial byproducts. To decode the complex patterns produced by VOCs, the researchers assessed the viability of integrating machine learning algorithms such as support vector machines (SVM), random forests, long short-term memory (LSTM) neural networks, and gradient boosting to classify sensor data and improve diagnostic accuracy. The models were assessed across bacterial cultures, infected tissues,
Image: Envisioned volatilomics and current genotypic and phenotypic workflows in medical microbiological pathogen and AMR diagnostics (Bilgin et al., Cell Biomaterials, 2025, DOI:10.1016/j.celbio.2025.100125)
Staphylococcus aureus, as well as detecting resistance profiles such as those involving extended-spectrum beta-lactamases. The researchers have emphasized the need for training these machine learning models on comprehensive datasets that reflect clinical variability to ensure robust performance. Ongoing efforts include miniaturizing devices for point-of-care use, functionalizing sensor surfaces, and mitigating environmental interference such as humidity and temperature. Although further development and clinical validation are necessary, these systems offer a clear path toward noninvasive, rapid diagnostics that can complement laboratory methods and support better antimicrobial stewardship.
≤30 minutes
qPCR Detection Kits (PCR fluorescence method):
Respiratory Diseases: COVID-19, fluA, fluB, AdV, TB and multiplex test
Blood Diseases: HBV, HCV, HIV and multiplex test
Sexually Transmitted Diseases: HPV, CT, NG, UU and multiplex test
Viral Zoonotic Diseases: MPV
Vector-borne Diseases: PF, ZIKV
Genetic Diseases: MTHFR
Animal Diseases: Swine/Avian/Aquatic
Animal/Ruminant/Companion Animal Diseases
Singu20 Nucleic Acid Extractor AccuRa-32 Real-Time PCR System (32 samples)
Singu20 Nucleic Acid Extractor AccuRa mini Real-Time PCR System (8-16 samples)
Multichem S is a tri-level, liquid-stable QC that monitors precision in clinical chemistry and immunology testing procedures. It mimics patient sample performance across 101 analytes, providing high stability and
Saliva-Based Cancer Detection Technique
which are time-consuming and costly. A newly developed saliva-based platform offers a promising alternative by allowing non-invasive detection of disease biomarkers with high accuracy. In earlier studies, the technology demonstrated strong sensitivity and specificity in identifying tumor mutations, particularly for non-small cell lung cancer, directly from saliva.
Researchers at the UCLA School of Dentistry (Los Angeles, CA, USA; dentistry.ucla.edu) developed a diagnostic platform known as EFIRM (Electric Field-Induced Release and Measurement), a liquid biopsy technology designed to isolate and analyze biomarker signals from biofluids such as saliva. The platform, which builds on more than two decades of research, eliminates the need for complex preparation and uses proprietary electric field-induced techniques to detect disease-related genetic material. The development of EFIRM has led to clinical advances in the detection of salivary biomarkers and has positioned the technology as a potential game changer in early, non-invasive diagnostics. The UCLA School of Dentistry has now entered a three-year sponsored research agreement with Dongwoon Anatech (Seoul, South Korea; www.dwanatech.com) to further optimize and clinically validate EFIRM for broader medical applications.
The collaboration will begin by refining protocols for D-SaLife, Dongwoon’s saliva-based glucose monitoring system, in diabetic and non-diabetic patients using samples from hospitals in the U.S. and South Korea. Later phases will focus on developing EFIRM I, a fully automated diagnostic device for cancers such as lung, gastric, and oral cancer, and co-developing EFIRM II, a next-generation, semiconductor-based platform with compact diagnostic cartridges for scalable, point-of-care use. While earlier studies confirmed the system’s clinical accuracy, the current research partnership will allow for expanded testing and device development aimed at real-world deployment. Researchers plan to evaluate performance across different populations, integrate semiconductor technologies for enhanced sensitivity, and eventually bring the system to clinical practice at scale.
“This collaboration reflects our shared vision to make early disease detection faster, simpler, and more accessible around the world,” said Dr. David T.W. Wong, professor at the UCLA School of Dentistry. “Dongwoon Anatech’s support brings us closer to realizing EFIRM’s potential in clinical settings.”
The Panther Plus scalable solution adds flexibility, capacity and throughput to the existing Panther system by allowing labs to load more consumables directly on the instrument, enabling even greater walkaway time.
Image: The steps involved in the electric field-induced capture and release (EFIRM) assay (Photo courtesy of UCLA School of Dentistry)
Self-Driving Microscope Tracks and Analyzes Misfolded Protein Aggregation in Real Time
The accumulation of misfolded proteins in the brain is central to the progression of neurodegenerative diseases like Huntington’s, Alzheimer’s, and Parkinson’s. Yet to the human eye, proteins that are destined to form harmful aggregates appear identical to normal ones, and these aggregates form rapidly and randomly—within minutes. Detecting and understanding the formation of such aggregates is crucial, as their biomechanical properties are directly linked to disease progression and disruption of cellular function. However, imaging tools that rely on fluorescent labels may alter cell properties and hamper accurate analysis. Now, researchers have developed a real-time imaging system capable of tracking protein aggregation dynamically and even predicting its onset before it begins.
The self-driving imaging system, developed by researchers at EPFL (Lausanne, Switzerland; www.epfl.ch), in collaboration with the European Molecular Biology Laboratory (Heidelberg, Germany; www.embl.org), builds on previous work involving deep learning algorithms that could detect mature protein aggregates in unlabeled images of living cells. The team developed two distinct algorithms. The first is an image classification
Cont’d on page 11
Cont’d from cover
Microneedle Skin Patch Detects Melanoma Without Biopsy or Blood Draw
elanoma, the most aggressive form of skin cancer, currently requires patients, especially those with fair skin and moles, to undergo regular doctor visits and biopsies every six months to determine if growths are malignant or benign. This process can be invasive, costly, and time-consuming. Traditional diagnostic methods often involve blood draws or surgical biopsies, making them inaccessible for routine, rapid screening. Detecting melanoma early is crucial to improving outcomes, but limitations in current testing options delay diagnosis and increase patient anxiety. Now, researchers have developed a skin patch and test strip that allow for non-invasive, rapid detection of melanoma without the need for a biopsy or blood sample.
ExoPatch, developed by researchers at the University of Michigan (Ann Arbor, MI, USA; www.umich.edu), is a silicone patch embedded with star-shaped microneedles that are just 0.6 mm long. These microneedles are coated with a gel containing Annexin V protein that attracts and captures exosomes, tiny vesicles released by cells from interstitial fluid in the epidermis. Once applied to the skin, the microneedles painlessly penetrate only the topmost layer without drawing blood. After 15 minutes, the patch is removed and placed in acid, dissolving the gel and releasing the exosomes into a solution. A test strip, similar to an at-home COVID-19 test, is then dipped into the solution: two lines indicate the presence of
melanoma exosomes, while one line indicates a negative result.
The ExoPatch was first validated on pig skin samples due to their similarity to human skin, with microscopy confirming microneedle penetration of 350 to 600 nanometers well within the epidermis. The system was then tested on tissue samples from mice, half of which had been injected with human melanoma tumor fragments. The patch successfully adhered to exosomes in the 30 to 150 nanometer range and was able to distinguish between melanoma and healthy tissue with a 3.5-fold darker test line for melanoma samples. The findings, published in Biosensors and Bioelectronics, showed that the patch isolated 11.5 times more exosomal protein from melanoma tissues, indicating high specificity. Future plans include a pilot study in humans followed by clinical trials. The gel coating of the ExoPatch could also be modified to detect exosomes from other solid tumors such as lung, breast, colon, prostate, and brain cancers.
“This is the first patch designed to capture disease-specific exosomes from fluid under the skin. The potential applications are huge,” said Sunitha Nagrath, co-corresponding author of the study.
Self-Driving Microscope Tracks and Analyzes Misfolded Protein Aggregation in Real Time
Cont’d from page 10
algorithm that activates a Brillouin microscope— normally too slow for live-cell imaging—only when it detects mature aggregates. Brillouin microscopy uses scattered light to characterize the biomechanical properties of aggregates, such as elasticity. The second algorithm is an “aggregation-onset” detection tool trained on fluorescently labelled images, capable of distinguishing subtle differences and predicting when aggregation will occur with 91% accuracy. This predictive function enables the microscope to be activated precisely when needed, capturing the biomechanics of protein aggregation as it unfolds.
The researchers tested and validated the system by observing the full dynamic formation of aggregates and measuring their properties in real time. Their findings, published in Nature Communications, demonstrated how self-driving microscopy could incorporate label-free methods for broader biological use. The ability to foresee and capture aggregation processes has significant implications for drug discovery and precision medicine, especially in targeting toxic oligomers suspected to drive neurodegeneration. Going
forward, the researchers aim to develop drug discovery platforms based on this technology to accelerate the development of more effective therapies for neurodegenerative diseases.
“This is the first publication that shows the impressive potential for self-driving systems to incorporate label-free microscopy methods, which should allow more biologists to adopt rapidly evolving smart microscopy techniques,” said EPFL PhD graduate Khalid Ibrahim, who led the collaborative effort.
Image: The newly designed ExoPatch successfully distinguished melanoma from healthy skin in mice (Photo courtesy of Jeremy Little/Michigan Engineering)
Image: The smart microscope can predict the onset of misfolded protein aggregation, a hallmark of neurodegenerative diseases (Photo courtesy of EPFL)
AUTOMATED NUCLEIC ACID EXTRACTION SANSURE BIOTECH
The Natch S Pro is a fully automated nucleic acid extraction system utilizing advanced magnetic beads technology for precise and efficient sample processing. It is capable of processing 576 tests per batch in less than 3 hours.
Evidence RABTA is a random-access biochip analyzer offering high-throughput testing with up to 2,640 results/hour. It allows walkaway operation for 2.5 hours and delivers results in as little as 36 minutes.
Uric Acid Testing Without Blood Draw
often lack affordable, non-invasive options for quick UA screening at home. Now, researchers have developed a paper-based test that provides instant, lab-free detection of UA levels using just a drop of saliva and a smartphone.
Scientists from Shaanxi University of Science and Technology (Xi’an, China; www.sust.edu.cn) have created “abnormal UA alarm,” a paper strip embedded with naphthylimide-derived fluorescent microparticles (NIFS) anchored to cellulose fibers. In water, these particles selfassemble into glowing lamellar structures under UV light, which dim proportionally when uric acid is present due to hydrogen bonding between the dye and UA. The darker the fluorescence, the higher the uric acid concentration. A smartphone app captures the color shift and calculates UA concentration by reading changes in the green channel of RGB values. The strip is entirely enzyme-free, electricity-independent, and integrates with a compact, credit-card-sized dark box that snaps onto smartphones, making the device user-friendly and highly portable.
A laboratory validation study, published in the Journal of Bioresources and Bioproducts, showed that the test detects UA concentrations as low as 0.91 μmol/L—well below the 250 μmol/L salivary threshold linked to hyperuricemia. Even when exposed to 34 common interferents like salts, amino acids, glucose, and dopamine, the strip’s fluorescence change remained UA-specific. In tests using real saliva, artificial urine, and food extracts, the tool yielded results with 95% to 108% accuracy, matching
enzyme-free gout screening for pennies per test (Photo courtesy of Shaanxi University)
traditional hospital assays. The strips are stable for at least six months at room temperature and cost less than one U.S. cent to produce. Researchers aim to launch an open-source testing kit later this year, with applications envisioned for use in homes, pharmacies, gyms, and low-resource clinics.
Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment
Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation techniques, may prematurely activate platelets, and often reduce their therapeutic effectiveness. These methods also involve complex equipment and handling that limit their use in low-resource or point-of-care settings. To overcome these challenges, researchers have developed a novel method that separates PRP directly from blood without requiring centrifugation. The new approach yields high-quality, minimally activated platelets, offering a cost-effective and portable alternative to existing methods.
This solution, developed at the University of the Basque Country (Leioa, Spain; www.ehu.eus), is a disposable, low-cost device based on gravity sedimentation, a process where denser particles settle under gravity. Unlike traditional centrifuge-based equipment, the system is made from laser-cut acrylic sheets and special adhesives, making it af-
fordable and easy to manufacture. This innovation is the result of over a decade of research into Lab-on-a-Chip technologies—compact systems that replicate laboratory functions on a single microdevice. During their studies, the team observed that plasma separated in these devices was rich in low-activated platelets, prompting a redesign for therapeutic purposes. The device can extract about 300 microliters of PRP from 1 milliliter of blood in 40 minutes and can be scaled for different blood volumes. The system was tested and validated through performance metrics, including platelet activation levels and blood component separation. Compared to traditional methods, platelet activation was significantly reduced to 8.2% from 31%, while maintaining the mean platelet volume crucial for PRP efficacy. It also eliminated 98% of red blood cells and 96% of white blood cells. The findings, published in Lab on a Chip, demonstrate the device’s potential for use in personalized treatments, resource-limited clinics, and home healthcare.
Cont’d from cover
Image: The fluorescent “abnormal UA alarm” delivers smartphone-guided,
Handheld Microfluidic Device Delivers
recommended, often due to inconvenience, cost, or lack of access. Now, a new portable device designed to deliver lab-quality A1C results in minutes aims to improve accessibility and frequency of monitoring.
Orange Biomed (Seattle, WA, USA; orangebiomed.com) has developed the OBM rapid A1c meter, a compact handheld device for diabetes testing. The system removes protein-based reagents to improve accuracy, and its patented Micro Electro-Mechanical System mimics human microvessels within a small cartridge. The meter requires only a minimal blood sample and guides users through a simple three-step process to produce immediate results in just five minutes anywhere.
The device is intended to encourage recommended monitoring frequency, leading to better diabetes management. It also has the potential to deliver more personalized care by enabling timely, preventive interventions. With its portable format, the technology could bridge gaps in diabetes monitoring across underserved communities and reduce the risks of diabetes-related complications.
“Using advanced microfluidic technology, our platform analyzes thousands of individual red blood cells from a single drop of blood within just five minutes; significantly reducing the sample size required and enabling faster, easier testing,” said Yeaseul Park, CEO and Co-Founder of Orange Biomed. “This isn’t simply a faster version of traditional testing; it’s a fundamentally new approach. We enable more precise HbA1c measurements, which are critical for diabetes care. Many remain under-monitored due to barriers to lab testing. Our solution brings high-quality monitoring into homes, clinics, and rural settings.”
“The potential of microfluidics extends far beyond diabetes. This technology enables personalized medicine, where treatment is based on each person’s unique biological profile,” added Unghyeon Ko, Co-Founder and President of Orange Biomed, who is spearheading R&D efforts. “As microfluidic systems evolve, we envision a future where more innovators apply this technology to medical devices to form multiplexed diagnostics that integrate genomics, proteomics, and metabolomics into a single, compact platform. Imagine a future where a device on your bathroom shelf can track immune status, detect early signs of cancer, or assess medication response, all from a few drops of blood. That future is closer than we think, and microfluidics is the gateway.”
ADLM MEETING OF THE MINDS
DEADLINE NOVEMBER 6
For submission info, visit meeting.myadlm.org
At the intersection of innovation and expertise, ADLM 2026 brings together the brightest minds in diagnostics and clinical laboratory medicine—all in one place.
If you’ve got insights to spark progress, questions to challenge the status quo, or data that deserves the spotlight, it’s time to share it.
Submit your proposal for the ADLM 2026 edition of Roundtables, ADLM University, and the core of the meeting, Scientific Sessions.
Image: The new HbA1c tech solves portable test accuracy challenges (Photo courtesy of Orange Biomed)
AUTOMATIC HEMATOLOGY ANALYZER
The LABAS F9000 is a fully automated hematology workstation designed for high-throughput clinical labs. With a modular design, it integrates complete blood count, specific proteins, and HbA1c testing.
Paper-Based Device Detects Immune Defects in 10 Minutes
rapid, highly sensitive paper-based test that enables one-step detection of these autoantibodies in under 10 minutes.
The paper-based diagnostic device called the 3D-osPAD (3D origami signal-amplified paper-based analytical device) has been developed by scientists at National Taiwan University (Taipei, Taiwan; www.ntu.edu. tw) and uses a folded 3D paper structure combined with gold nanoparticle signal amplification to enhance detection. All necessary reagents are preloaded within layered compartments, which allows the assay to initiate automatically once a small drop of diluted blood serum is added. The design enables a one-step, streamlined process that does not require expensive laboratory equipment or specialized training, making it accessible for both hospital and remote clinical settings. This technological innovation significantly improves test sensitivity achieving a tenfold increase over conventional detection methods while delivering results in just 10 minutes.
In the study published in Biosensors and Bioelectronics, the 3D-osPAD was clinically validated and demonstrated 100% sensitivity and specificity in accurately identifying patients with adult-onset immunodeficiency caused by anti-IFN-γ autoantibodies. In addition to its clinical accuracy, the portable and user-friendly design of the test supports applications in rapid diagnosis, treatment planning, and recovery monitoring. The researchers
URINE CHEMISTRY CONTROL QUANTIMETRIX
Dropper Urine Chemistry Control is a liquid control made from human urine for monitoring routine and stat assays. It is compatible with major analyzers including Siemens, Beckman Coulter, Abbott, and Roche.
curacy for adult-onset immunodeficiency
University)
plan to further develop similar user-friendly and highly sensitive analytical tools for on-site diagnostics, especially in resource-limited environments.
Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments
Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through a radiation field absorbs small amounts of energy that, cumulatively, can weaken the immune system or trigger hematologic toxicity. A new model now offers a way to measure this exposure and improve the safety of cancer treatment.
Researchers at the University of Navarra (Pamplona, Spain; en.unav. edu) have developed the FLIP-HEDOS method, the first tool to quantify radiation absorbed by blood during therapy. By combining patient anatomy, blood circulation data, and radiotherapy plans, it simulates when and how much blood is irradiated. This approach treats blood as an “organ at risk” and integrates insights from physics, oncology, and engineering to guide personalized radiotherapy planning.
The researchers conducted a study along with clinicians to validate the framework in a real clinical setting. The results showed that factors such as tumor proximity to major blood vessels, the type of radiation applied, and variations in cardiac output significantly shaped blood irradiation. Findings emphasize that even low doses can damage lymphocytes, impairing immune responses during cancer treatment.
FLIP-HEDOS has gained recognition at leading international forums, including the European Society for Radiotherapy and Oncology (ESTRO) in Austria (May 2025), the Radiation Research Society Conference in the U.S. (September 2024), and the Spanish Society of Medical Physics (May 2025). Portions of the work have also been published in journals such as Radiation Physics and Chemistry, Physics in Medicine & Biology, and Clinical Cancer Research. These achievements highlight the tool’s credibility and its potential role in advancing radiation oncology.
Beyond radiotherapy planning, the method could be applied to simulate drug or radiopharmaceutical distribution and to evaluate strategies for radioprotection. Modeling cumulative exposure creates opportunities to optimize treatment schedules and beam directions to reduce blood damage. Researchers see it as a paradigm shift toward protecting the immune system and enhancing patients’ quality of life in precision oncology.
“Thinking of blood as a dynamic organ to be protected represents a paradigm shift in modern radiotherapy,” said Professor Javier Burguete, Professor of Medical Physics and Biophysics at the University of Navarra and director of the thesis. “This research not only responds to a scientific need, but also a clinical imperative: to offer safer treatments without compromising oncological efficacy.”
Cont’d from cover
Image: The 3D paper-based analytical device has shown high clinical ac-
(Photo courtesy of National Taiwan
Portable Spectroscopy Rapidly Detects Bacterial Species in Vaginal Fluid
aginal health depends on maintaining a balanced microbiome, particularly certain Lactobacillus species. Disruption of this balance, known as dysbiosis, can increase risks of infection, pregnancy complications, and other long-term health issues. Existing diagnostic methods often fail to detect Lactobacillus iners, a key protective bacterium, or identify early microbiome changes. Now, a new optical approach offers a faster, noninvasive way to spot microbial imbalances.
Researchers at Vanderbilt University (Nashville, TN, USA; www. vanderbilt.edu) tested surface-enhanced Raman spectroscopy (SERS), a technique that captures biochemical fingerprints from vaginal fluid. In a pilot study, they collected samples from 19 participants during routine exams and analyzed them using both a laboratory Raman microscope and a portable Raman spectrometer. The SERS spectra revealed proteins, lipids, organic acids, and sugars. The team then used a separate molecular technique, quantitative PCR, to identify key microbes in each sample.
The study, published in Biophotonics Discovery, compared spectral profiles to molecular results from quantitative PCR. Gardnerella vaginalis, linked to bacterial vaginosis, produced elevated protein and lipid signals with reduced organic acids. Lactobacillus iners showed higher organic acid levels and fewer protein and polysaccharide signals. These trends matched known microbial effects on the vaginal environment and were visible with both lab and portable systems.
Notably, G. vaginalis signatures were found in samples from participants without symptoms or diagnosed infections, suggesting the method can detect early or subclinical microbiome shifts. The portable Raman spectrometer produced results comparable to benchtop systems, showing the technology’s potential for point-of-care use without a full lab setup.
New Miniature Device to Transform Testing of Blood Cancer Treatments
Chimeric antigen receptor (CAR) T cell therapy has emerged as a groundbreaking treatment for blood cancers like leukemia, offering hope to patients when other treatments fail. However, despite its promise, nearly half of leukemia patients relapse, and many suffer from serious side effects. Efforts to improve CAR T therapies have been hampered by the limitations of conventional testing methods. Traditional models fail to accurately replicate the complex human immune response and the bone marrow environment where leukemia develops. Now, researchers have developed a new solution to bridge this gap—a platform that allows for real-time observation of cancer treatment interactions under controlled conditions, offering a more accurate and patient-specific approach to testing blood cancer therapies.
This innovative platform, termed “leukemia-on-a-chip,” was developed through a collaboration between the Perelman School of Medicine at the University of Pennsylvania (Philadelphia, PA, USA; med.upenn.edu) and the Tandon School of Engineering at New York University (Brooklyn, NY, USA; engineering.nyu.edu). The device is the first to successfully recreate the physical and immunological environment of human bone marrow on a microscope slide-sized chip. It integrates three distinct bone marrow regions—blood vessels, surrounding marrow cavity, and the outer bone lining—and when seeded with patient-derived cells, it self-organizes to produce structural proteins such as collagen, fibronectin, and laminin. Importantly, the device preserves the immune cell activity within the marrow microenvironment. The system incorporates vascular networks to simulate realistic immune interactions in three dimensions, providing a level of insight and accuracy far beyond 2D cultures or animal models. The development is also timely, coinciding with the FDA’s new roadmap to reduce animal testing requirements in drug development.
In their study published in Nature Biomedical Engineering, the researchers used advanced imaging to watch CAR T cells move through
Cont’d on page 16
Image: SERS captures the spectra of vaginal fluid samples to detect biochemical changes in relation to bacterial presence (Photo courtesy of A. Rourke-Funderburg/Vanderbilt Biophotonics Center)
This approach could support routine vaginal health monitoring and earlier intervention for microbiome imbalances. While the pilot study assessed only a few bacterial species, future research will expand the participant pool and employ genetic sequencing for broader microbial coverage. The findings lay the groundwork for less subjective, more accessible diagnostics in women’s health.
INVITEDTOAPPLY DISTRIBUTORS
STERILIZABLE INSTRUMENT & WORK-SURFACE MATS
Thermo-Resistant (- 60 °C to 300 °C)
Fully Washable & Flexible
Suitable for central sterilization services
Sterilizable
The iFlash 9000 is a high-throughput chemiluminescence immunoassay analyzer designed. It supports up to 600 tests per hour and offers excellent performance with a capacity of 40 reagent positions and 3000 reaction vessels.
Platform Leverages AI and Quantum Computing to Predict Salmonella Antimicrobial Resistance
Antimicrobial-resistant Salmonella strains are a growing public health concern due to the overuse of antimicrobials and the rise of genetic mutations. Accurate prediction of resistance is crucial for effective treatment, yet traditional methods such as bacterial antimicrobial susceptibility tests (ASTs) are inefficient. Predictive models based on whole-genome sequencing (WGS) data also face challenges, particularly overfitting due to the high dimensionality of genomic data. Additionally, these models struggle with imbalances in the number of resistant and sensitive samples, further limiting their reliability. Now, researchers have developed an innovative prediction platform that integrates advanced artificial intelligence (AI) and quantum computing technologies to improve accuracy and efficiency in antimicrobial-resistance prediction.
The new solution, developed by scientists at Sichuan University (Chengdu, China; en.scu.edu.cn), is called the Salmonella AntimicrobialResistance Predictive platform based on Large Language Models (SARPLLM). It employs a two-step feature-selection process that begins with a chi-square test and conditional mutual information maximization to identify key resistance genes through pan-genomic analysis. The SARPLLM algorithm itself is based on the Qwen2 large language model and incorporates low-rank adaptation (LoRA) to convert Salmonella samples into sentence-like structures for AI processing.
To resolve data imbalance, the researchers created the QSMOTEN algorithm—an advancement of the SMOTEN method that uses quantum computing to encode genomic features into quantum states and calculate sample distances more efficiently, reducing computational complexity from linear to logarithmic scale. In addition, the team launched a user-friendly online platform built with Django as the backend and Echarts for knowledge graph visualization. It includes modules for resistance prediction, pan-genomic results, gene-antimicrobial interaction mapping, and data downloads.
Experimental validation showed that SARPLLM achieved higher F1-scores than existing models for multiple antimicrobials, while QSMOTEN demonstrated strong performance on both virtual and physical quantum machines in computing genomic similarities. The study, published in Engineering, confirms that combining AI with quantum computing can significantly accelerate and enhance resistance prediction. The platform’s practical utility is strengthened by its ability to provide online data processing, visualization, and downloadable results.
However, researchers noted that current large language models still struggle to fully grasp the complex biological and genetic foundations
RADIAL IMMUNODIFFUSION ASSAY LINEAR CHEMICALS
The C3 ID test is a radial immunodiffusion assay for quantifying Complement C3 in human serum. Featuring pre-coated plates and a built-in calibration curve, it ensures reproducible results for immune monitoring.
Image: The groundbreaking salmonella antimicrobial resistance prediction platform has demonstrated 95% accuracy (Photo courtesy of Yujie You et al., DOI: 10.1016/j.eng.2025.01.013)
of antimicrobial resistance, and that the accuracy of predictions is influenced by the quality of training data. The team plans to integrate multi-source data and domain-specific knowledge in future iterations and to advance more stable quantum hardware to improve performance further.
New Miniature Device to Transform Testing of Blood Cancer Treatments
Cont’d from page 15
blood vessels, detect cancer cells, and destroy them—processes previously impossible to view with this clarity. They observed that engineered immune cells not only targeted leukemia cells but also activated other immune cells nearby in a “bystander effect” that may explain both therapeutic success and some side effects. The team simulated different patient responses, including remission, relapse, and resistance, and demonstrated that newer, fourth-generation CAR T cells performed better than standard versions, even at lower doses. The chip setup takes just half a day to assemble and supports experiments for up to two weeks, in contrast to animal models that require months. Going forward, the researchers aim to use this platform to test individual patient cancer cells against various treatment designs, enabling a personalized approach to therapy selection before treatment begins.
Edited by Marilena Stamouli, BSc, MS
MESSAGE FROM THE PRESIDENT
By Tomris Ozben • President, IFCC
Dear
Colleagues and Friends, I hope this message finds you well and that you have enjoyed a restful summer season.
Summer is always a unique moment of the year, a time to pause from our busy routines, to reconnect with family and friends, and to recharge our energies. It also offers us the opportunity to reflect on the progress we have made together and to look ahead with renewed enthusiasm to the many activities, projects, and challenges awaiting us in the coming months.
The 179th IFCC Executive Board Meeting Conference Call was held on July 14 and July 23, 2025 (second part of the 179th meeting) to discuss some important and urgent agenda items.
On July 24, 2025, I attended the half-year meeting of the Joint Committee for Traceability in Laboratory Medicine (JCTLM) Executive Committee meeting. The JCTLM President, Mauro Panteghini and Executive Secretary, Robert Wielgozs organized the meeting with the JCTLM representatives of partner organizations and we discussed several agenda items.
I had the pleasure of attending the 2025 ADLM Annual Meeting which was held July 27-31, 2025, in Chicago, Illinois, USA. I was delighted to attend the opening and scientific sessions, great exhibition and meeting with several colleagues. During the ADLM meeting, it is customary for the leadership of ADLM and IFCC to meet and provide updates on each organization and to discuss areas of collaboration. Representatives from IFCC and ADLM Boards attended the leadership meeting on Tuesday, July 29, 2025, from 1:00-2:00 p.m. at the McCormick Place Convention Centre.
We exchanged and updated information about our activities and discussed areas of interest and the potential collaborations. It was an excellent opportunity to meet in person, exchange ideas, and strengthen our collaboration for the benefit of the global laboratory medicine community.
I would like to inform you that WHO has formed the WHO Diagnostics Task Force in 2023 supporting the Global Diagnostics Coalition. I attended the WHO Global Diagnostics Coalition virtual/ zoom meeting held on 13 August 2025, since IFCC
IFCC WORLDLAB NEW DELHI 2026
25-29 OCTOBER 2026
India International Convention & Expo Centre
www.ifccnewdelhi2026.org
Cont’d from page 17
Message from the President
has an agreement with WHO as its partner, and IFCC is the biggest diagnostic organization. Many WHO Diagnostic Coalition members attended the meeting, including several Radiology organizations and WASPaLM.
The agenda for the virtual meeting included discussion of WHA Resolutions 76.5 and 78.13, as well as sharing information on other WHO-led diagnostic and health networks.
WHA Resolutions 76.5 and 78.13 address diagnostic requirements across multiple health conditions like infections, pandemics, rare diseases, emergencies and non-communicable diseases.
The WHO Diagnostic Taskforce was created to align WHO staff efforts on diagnostics and to ensure the harmonized implementation of WHA76.5. It comprises senior management, coordination teams, and over 100 technical experts.
WHA76.5 calls for improved data collection on accessibility and availability, updates to essential diagnostics lists, and strengthened health technology management. Under WHA76.5, Member States are expected to develop and implement national diagnostic strategies, invest in research and development as well as workforce training, and ensure equitable and timely access to diagnostic services.
WHA78.13 focuses on strengthening medical imaging capacity, requesting WHO technical assistance for policy implementation, updates to the priority medical device lists, and the promotion of sustainability in imaging technologies.
Other examples are like the Global Accelerator for Paediatric Formulations (GAP-f). GAP-f addresses the gap in paediatric medicines, aiming to accelerate research, development, and access to child-friendly formulations. It was legitimized through a 2016 WHO resolution and operationalized with a strategic business plan.
The development of the program is structured in three phases: the first focused on building trust and collaborative models; the second concentrated on testing the platform and integrating new therapeutic areas; and the third aims to consolidate operations to improve efficiency and sustainability.
GAP-f operates with a lean and flexible model, organizing working groups for research, product development, regulatory affairs, and access, supported by streamlined governance. Activities are prioritized based on community impact and capacity to execute, focusing on study design, clinical research, and product introduction. Lessons learned highlight accountability, structured engagement, efficient governance, and collaborative fundraising. Its Impact Measurement Framework ensures equitable access to paediatric medicines. Stakeholder engagement with private sector, civil society, funders, regulators, and governments drives progress. GAP-f has strengthened its membership and funding, delivering results through collaboration and innovation.
The strategic roadmap aligns priorities, accelerates research, catalyses development, and supports safe rollout, aiming to transform the paediatric medicines ecosystem. Overall,
GAP-f demonstrates an agile, collaborative approach to improving children’s healthcare globally.
The 2025 Taskforce Workplan emphasizes quality management systems and the application of artificial intelligence in diagnostics, along with engagement with suppliers of diagnostics for HIV and other priority diseases.
Overall, the Global Diagnostics Coalition is a WHO managed network that seeks to enhance global diagnostic access and capacity, foster collaboration among diverse stakeholders, and promote the integration of diagnostics into national health strategies as a cornerstone of effective health systems.
Looking ahead, our next Executive Board meeting will take place in October in the beautiful city of Sinaia, Romania, during the 32nd Meeting of the Federation of Balkan Clinical Laboratories, which will take place alongside the 16th National Conference of the Romanian Association of Laboratory Medicinal, from October 8 to 11, 2025. This will provide an important occasion for us to gather in person once again and discuss the new priorities and challenges of IFCC.
I would also like to highlight the series of webinars scheduled for the coming months, which represent one of the most dynamic and accessible educational initiatives of IFCC. These online sessions cover a wide range of topics in laboratory medicine, bringing together leading international experts who generously share their knowledge and experience, ensuring that valuable educational content reaches scientists in every region, regardless of geographical or economic barriers.
And let me take this chance to remind you that WorldLab 2026, the 27th International Congress of Clinical Chemistry and Laboratory Medicine, will take place in the vibrant city of New Delhi, hosted by the Association of Clinical Biochemists of India (ACBI) together with IFCC and APFCB.
The Congress will take place at the India’s largest International Convention and Exhibition Centre (Yashobhoomi, IICC), located in Dwarka, New Delhi, 10 km from Indira Gandhi International Airport and Aerocity and 25 km from the city centre of New Delhi. The venue offers seamless connectivity, with a metro station located inside the congress centre, connecting IICC to the Airport, Aerocity hotels and central New Delhi. Accommodations are plentiful, with 3,500 hotel rooms available near the IICC complex and an additional 3,600 rooms in the adjacent Aerocity.
Please mark October 25-29, 2026, in your calendar to attend IFCC Worldlab in New Delhi, India. Join us for an extraordinary opportunity to engage with leading experts and scientists in our field. Your presence promises to elevate the 27th IFCC WorldLab into a truly unforgettable congress.
Looking forward to a very productive fall season for IFCC member societies, national federations, and colleagues from around the world.
With my best regards, Prof. Dr. Tomris Ozben IFCC President
www.amlr.medical-congresses.ro
IFCC Experts Deliver Lectures at 3rd Algerian Workshop on Flow Cytometry
By Evan Ntrivalas,
The 3rd Algerian Workshop on Flow Cytometry took place in Algiers, Algeria, from June 20 to June 23, 2025. The workshop was organized by the Algerian Society of Immunology, under the auspices of IFCC. Dr Evan Ntrivalas, the current Chair of the WG-FC, participated in person in the workshop.
The workshop was a great success. The Organizing Committee, consisting of Pr. A. Tahiat, Pr. K. Djenouhat, Pr. C. Lambert and Pr. M. Brahimi, put together an excellent 4-day workshop that included lectures, tutorials, and practical sessions. International speakers included Dr Evan Ntrivalas from New York (representative of IFCC), Dr Alberto Orfao from Spain (representative of EuroFlow), Dr Iuri Marinov from Czech Republic, Dr Tezaghdenti Aymen from Tunisia and Dr Anis Larbi from France (representative of Beckman Coulter). Beckman Coulter provided the flow cytometer for the handson practical sessions. These sessions were commercial free with no bias from the company. Other companies that participated in
the workshop were BD, Amgen, Thermo Fisher, and I.M.D. Laboratories.
Participants had the chance to visit the various booths during the breaks and receive educational materials related to their interest. The content of the workshop included a wide range of topics, from basic immunology, basic flow cytometry and advanced clinical applications of flow cytometry in immune deficiencies, to hematological malignancies and transplantation. The hands-on practical sessions facilitated and completed the understanding of the lectures. The entire 4-day program is provided as an addendum at the end of the report.
The workshop participants were both immunologists and hematologists, all from regions of Algeria. There were more than 150 applicants for this workshop, but due to space and resource limitations, the organizing committee limited the number of workshop participants to 35. Nevertheless, the large number of applicants emphasizes the need for similar work-
shops and the great role IFCC is playing to ensure their continuation. The 35 participants were vibrant attendees, asking questions for deeper understanding, requesting more information and trying to get the best out of the sessions. The practical hands-on sessions were a great success. Notably, participants in these sessions did not mind about the time allotted for each one, and there were several that went well above the ending time, driving the sessions in the early evening hours. It was obvious that participants were there to learn and time was not an issue. There were also various coffee breaks and social sessions, during which the participants had the chance to network and discuss with faculty members. At the end of the workshop participants gave excellent remarks and positive feedback for the whole experience.
Overall, it was a very well organized and attended workshop. IFCC was mentioned several times and its contribution to the workshop’s success was very well noted.
Chair of the IFCC Flow Cytometry Working Group (WG-FC)
My Experience with the IFCC Exchange Program at Laboratory in Paris, France
Ihad the opportunity to participate in the IFCC-PSEP from March 3rd to May 30th, at the Laboratoire de Biochimie Métabolique et Nutrition, Hôpital Bichat Claude-Bernard, Paris, France.
During my stay, I gained theoretical, as well as practical knowledge about Congenital Disorders of Glycosylation (CDG). I was trained in the processing and interpretation of laboratory analyses related to CDG diagnosis, such as capillary electrophoresis of Transferrin isoforms, 2D electrophoresis of Apolipoprotein CIII and other plasma proteins, and western blotting of proteins like Transferrin and Antithrombin III. At the same time, I was able to actively participate in novel lines of research related to the application of Antithrombin III as a potential biomarker for CDGs and the use of sorbitol dehydrogenase activity as a biomarker for Charcot-Marie-Tooth disease.
I can confidently say that I worked alongside a marvelous group of professionals, who not only welcomed me but also encouraged my involvement and participation in a variety of activities, both inside and outside the lab, making the
Don’t
By Jose Manuel Larramendi Embid
experience unforgettable.
Apart from my laboratory work, living abroad was both an enriching and adventurous experience. I had the chance to experience Paris from a local’s perspective, discovering its lifestyle, cuisine and culture, truly a mind opening opportunity.
I now see the IFCC-PSEP as the beginning of a broader journey into the international scene of clinical chemistry. This experience motivated me to keep participating in scientific activities, such as congresses and webinars, and to further deepen my studies in this beautiful science. Thanks to the IFCC-PSEP, I presented a CDG clinical case study at the XV Uruguayan Congress of Clinical Chemistry, helping introduce this topic to many Uruguayan and Latin American colleagues.
I highly recommend the participation of young scientists in the IFCC-PSEP as I can assure it represents a unique opportunity to experience clinical chemistry from a different perspective.
I would like to personally thank Dr. Elodie Lebredonchel, Professor Kattel Peoc’h, and every member of the Laboratoire de Biochimie Métabolique et Nutrition, Hôpital Bichat Claude-Bernard, that made my stay so memorable. I also thank the Uruguayan Biochemistry Association that encouraged and supported my exchange.
Miss Your Chance – Apply Now for the UNIVANTS of Healthcare Excellence awards
With over 85 recognized best practices to date through the UNIVANTS of Healthcare Excellence award program, and engagement in over 100 countries, it is evident that healthcare excellence is happening globally. With that comes the next opportunity for global recognition as the UNIVANTS program is now accepting applications for 2026 recognition. If you are passionate about healthcare excellence, are actively collaborating across disciplines, and measuring improvements of strategic laboratory-enabled, clinically-focused initiatives, now is the time to apply.
Updated award criteria is now available on the UNIVANTs website, and (but
are not limited to) include requirements around laboratory medicines direct and substantiated role in the initiative, as well as key performance indicator requirements that link directly to a health benefit. Before starting your application, please review them closely.
Partners of the UNIVANTS of Healthcare Excellence award program include Abbott, International Federation of Clinical Chemistry and Laboratory Medicine (IFCC), Association for the Diagnosis of Laboratory Medicine (ADLM, formerly branded as AACC), Modern Healthcare, National Association for Healthcare Quality (NAHQ), European Health Management Association (EHMA), Institute of Health Economics (IHE), Healthcare Information and Management Systems Society (HIMSS). Applications must be free from industry bias and do not take into account any product or partner affiliation upon scoring, The award program recognizes valued and innovative healthcare teams by recognizing, amplifying, and celebrating best practices in healthcare that are facilitated through insights, engage-
ment and leadership fueled by laboratory medicine.
Apply today and spotlight the excellence happening in Latin America and inspiring others to achieve the same, because “recognition is not a reward for success—it’s a catalyst for it. When we celebrate achievements, we multiply their impact.”
For more information on how to apply, to learn about past winners, best practice examples and/or to apply for global recognition before the November 15th deadline, please visit www.UnivantsHCE.com.
IFCC OFFICE
Via Carlo Farini 81, 20159 Milan, ITALY Tel: (39) 02-6680-9912 • E-mail: ifcc@ifcc.org Web: www.ifcc.org
The views and positions expressed in the IFCC News section are those of the IFCC or the individual authors, and do not necessarily represenT the views or positions of LabMedica magazine or its publishers
Tempus AI Acquisition Expands
Tempus AI (Chicago, IL, USA; tempus.com York, NY, USA; artificial intelligence (AI) company specializing in digital pathology. The acquisition allows Tempus to grow its dataset, expand its experienced technical team, and establish a strong footprint in digital pathology with an industry-leading technology portfolio.
Founded in 2017, Paige has developed and deployed several AI applications, including the first FDA-cleared AI application in pathology,
iemens Healthineers (Forchheim, Germany; com) has entered into a strategic agreement with Carna Health (Boston, MA, USA; www.carna.health adoption of Carna’s artificial intelligence (AI)-enabled CKD platform and bring industry-leading point-of-care testing systems
ntiphospholipid syndrome (APS) is a rare autoimmune disorder that increases blood coagulability, elevating the risk of thrombotic events such as stroke, myocardial infarction, pulmonary embolism, and DVT. It is also associated with recurrent miscarriages. Diagnosis currently relies on blood tests that require repeat confirmation over time, underscoring the need for faster, more reliable tools.
To address this gap, VolitionRx (Henderson, NV, USA; www.volitionrx.com epigenetics company, has signed a research license and exclusive commercial option rights agreement for APS with Werfen’s Immunoassay Technology Center (Barcelona, Spain; werfen.com). Under the agreement, Werfen will evaluate the clinical utility of Volition’s proprietary Nu.Q® NETs assay on its automated platforms. The assay focuses on detecting neutrophil extracellular traps (NETs), which play a significant role in the clotting complications seen in APS patients.
Initial technology transfer has already succeeded, with the Nu.Q® NETs assay integrated into Werfen’s ACL AcuStar® platform. Early data on NET detection in APS
2025
OCTOBER
54th Mexican Congress of Clinical Pathology – Mexican Federation of Clinical Pathology. Oct 1-4; Guadalajara, Mexico; fempac.org.mx
JFBM 2025 – Journées Francophones de Biologie Médicale. Oct 8-10; Cannes, France; jfbm.fr
32nd Meeting of the Federation of Balkan Clinical Laboratories (BCLF) & 16th National Conference of the Romanian Association of Laboratory Medicine (AMLR). Oct 8-11; Sinaia, Romania; amlr.medical-congresses.ro
16th National Congress of Clinical Laboratory Technicians of Panama. Oct 9-11; Panama City, Panama; conalac.com
47th ISOBM Conference - International Society of Oncology and Biomarkers. Oct 13-15, Murnau am Staffelsee, Germany; isobm.org
62nd Annual Scientific Conference of the Australasian Association of Clinical Biochemistry and Laboratory Medicine (AACB). Oct 13-16; Auckland, New Zealand; aacb.asn.au
34th WASPALM & 51st ACBICON 2025 – World Congress of Association of Societies of Pathology and Association of Clinical Biochemists of India. Oct 14-17; Pune, India; waspalm2025.org
ASHG 2025 – Annual Meeting of the American Society of Human Genetics. Oct 14-18; Boston, MA, USA; ashg.org
38th JNBC – National Days of the Tunisian Society of Clinical Biology (STBC). Oct 16-18; Tunis, Tunisia; macsievents.com/stbc
First Annual Meeting of the Emirates Clinical Chemistry Society (ECCS) and the Digital Health & Laboratory Medicine Forum. Oct 17-18; Dubai, UAE; eccsforum.com
WHX Labs Nairobi 2025. Oct 22-24; Nairobi, Kenya;
worldhealthexpo.com
DKLM 2025 – Annual Congress of the German Society for Clinical Medicine and Laboratory Medicine (DGKL). Oct 23-24; Leipzig, Germany; laboratoriumsmedizin-kongress.de
27th National Congress of the Society of Medical Laboratory Technology of South Africa (SMLTSA). Oct 24-26; Stellenbosch, South Africa; smltsa.org.za
ISBT Perth 2025 – Regional Congress of the International Society of Blood Transfusion. Oct 26-29; Perth, Australia; isbtweb.org
WSPID 2025 – 14th World Congress of the World Society for Pediatric Infectious Disease. Oct 28-31; Bangkok, Thailand; wspid2025.com
TBS Internatinal Laboratory Medicine Summit - Turkish Biochemical Society. Oct 28-31; Erzurum, Turkey; biyokimyakongresi.org
LMCE-KSLM 2025 – Laboratory Medicine Congress & Exhibition and 66th Annual Meeting of the Korean Society of Laboratory Medicine. Oct 29-31; Incheon, Korea; lmce-kslm.org
23rd Greek National Congress of Clinical Chemistry. Oct 30 - Nov 2; Thessaloniki, Greece; eekx-kb.gr
NOVEMBER
APCCMI 2025 – 20th Asia Pacific Congress of Clinical Microbiology and Infection. Nov 2-4; Bangkok, Thailand; apccmi2025.com
6th SMLC Congress – Chilean Medical Society of Clinical Laboratory (SMLC). Nov 5-6; Santiago, Chile; smlc.cl
57th SIBioC National Congress – Italian Society of Clinical Biochemistry and Molecular Biology. Nov 5-7; Bologna, Italy; sibioc.it
8th ESPT Congress – European Society for Pharmacogenomics and Personalised Therapy. Nov 5-8; Rotterdam, Netherlands; esptcongress.org
73rd Annual Scientific Meeting of the American Society of Cytopathology (ASC). Nov 5-9; St. Louis, MO, USA; cytopathology.org
65th Annual Academic Assembly of the Japan Society of Clinical Chemistry (JSCC). Nov 7-9; Nagoya, Japan; jscc-jp.gr.jp
AMP 2025 – Association for Molecular Pathology
Annual Meeting & Expo. Nov 11-15; Boston, MA, USA; amp25.amp.org
LABCLIN 2025 – 19th Spanish National Congress of Laboratory Medicine. Nov 12-14; Valencia, Spain; labclin.org
Annual Meeting of the RBSLM – Royal Belgian Society of Laboratory Medicine. Nov 13-14; Brussels, Belgium; rbslm.be
47th Annual Conference of the Association of Clinical Biochemists in Ireland (ACBI). Nov 14-15; Athlone, Ireland; acbi.ie
46th Annual Meeting of the American College of Toxicology (ACT). Nov 16-19; Phoenix, AZ, USA; actox.org MEDICA 2025. Nov 17-20; Dusseldorf, Germany; medica-tradefair.com
ASCP 2025 – Annual Meeting of the American Society for Clinical Pathology. Nov 17-20; Atlanta, GA, USA; ascp.org
ASLM Special Convention on Diagnostics 2025 – African Society for Laboratory Medicine. Nov 25-27; Nairobi, Kenya; aslm.org
DECEMBER
11th Annual Conference of the Saudi Society for Clinical Chemistry (SSCC). Dec 1-3; Riyadh, Saudi Arabia; sscc.med.sa
ASI 2025 – Annual Scientific Meeting of the Australian and New Zealand Society for Immunology. Dec 1-5; Perth, Australia; immunology.org.au
67th Annual Meeting & Exposition of the American Society of Hematology (ASH). Dec 6-9; Orlando, FL, USA; hematology.org
7th EFLM Conference on Preanalytical Phase. Dec 1213; Padua, Italy; eflmpreanalytical.org
AMBICON 2025 - 32nd Annual National Conference of Association of Medical Biochemists of India. Dec 1214; Coimbatore, India; ambicon2025.org
2026
FEBRUARY
50th Labquality Days 2026 – International Congress on Quality in Laboratory Medicine. Feb 5-6; Helsinki,
Finland; labqualitydays.fi
SLAS2026 International Congress & Exhibition. Feb 711; Boston, MA, USA; slas.org
WHX Labs Dubai 2026. Feb 10-13; Dubai, UAE; worldhealthexpo.com
5th International Laboratory Diagnostics Congress. Feb 15-18; Virtual; ldcongress.com
MARCH
35th Annual Meeting of the Society of Virology (GfV). Mar 17-20; Heidelberg, Germany; virology-meeting.de
USCAP 115th Annual Meeting – United States and Canadian Academy of Pathology. Mar 21-26; San Antonio, TX, USA; uscap.org
CACLP 2026 – 23rd China International In Vitro Diagnostic Expo. Mar 21-23; Xiamen, China; en.caclp.com
APRIL
Immunology 2026 – Annual Meeting of the American Association of Immunologists (AAI). Apr 15-19; Boston, MA, USA; aai.org
ESCMID Global 2026. Apr 17-21; Munich, Germany; escmid.org
ISLH 2026 Congress – International Society for Laboratory Hematology. Apr 17-19; Edinburgh, Scotland, UK; islh.org
Expolab 2026 – 26th Mexican National Congress of Clinical Chemistry and Laboratory Medicine. Apr 30 - May 3; Puebla, Mexico; fenacqc.org.mx
MAY
SLAS Europe 2026 Conference and ExhibitionSociety of Laboratory Automation and Screening. May 19-21; Vienna, Austria; slas.org
Hospitalar 2026. May 19-22; Sao Paulo, Brazil; hospitalar.com
109th Annual Meeting of the German Society for Pathology (DGP). May 28-30; Augsburg, Germany; pathologie-dgp.de
JUNE
WHX Labs Lagos 2026. Jun 2-4; Lagos, Nigeria; worldhealthexpo.com
ICE 2026 – 22nd International Congress of Endocrinology. Jun 2-6; Kyoto, Japan; isendo.org
ASM Microbe 2026 – American Society for Microbiology. Jun 4-8; Washington, DC, USA; asm.org
FOCIS 2026 – Annual Meeting of the Federation of Clinical Immunology Societies. Jun 9-12; San Francisco, CA, USA; focisnet.org
EAACI 2026 – Annual Congress of the European Academy of Allergy & Clinical Immunology. Jun 1215; Istanbul, Turkey; eaaci.org
ESHG 2026 Hybrid Conference – European Society of Human Genetics. Jun 13-16; Gothenburg, Sweden; 2026.eshg.org
AMP Europe 2026 - Association for Molecular Pathology. Jun 15-17; Tallinn, Estonia; amp-europe-congress.com
WHX Miami 2026. June 17-19; Miami, FL, USA; worldhealthexpo.com
11th FIDSSA Congress – Federation of Infectious Diseases Societies of Southern Africa. Jun 18-20. Cape Town, South Africa; fidssacongress.co.za
51st CBAC – Congress of the Brazilian Society of Clinical Analysis. Jun 28 - Jul 1; Rio de Janeiro, Brazil; sbac.org.br/cbac
ECB 2026 – European Congress on Biotechnology. Jun 28 – Jul 1; Antwerp, Belgium; efbiotechnology.org
JULY
50th FEBS Congress – Federation of European Biochemical Societies. Jul 4-8; Maastricht, Netherlands; febs.org
WHX Labs Kuala Lumpur 2026 (formerly Medlab Asia). Jul 13-15; Kuala Lumpur, Malaysia; worldhealthexpo.com
ASV 2026 – 45th Annual Meeting of the American Society of Virology. Jul 27-30; Minneapolis, Minnesota; asv.org
SEPTEMBER
Thailand Lab International 2026. Sep 2-4; Bangkok, Thailand; thailandlab.com
ECP 2026 – 38h Congress of the European Society of Pathology. Sep 12-16 Stockholm, Sweden; esp-pathology.org
EUROTOX 2026 – 60th Congress of the European Societies of Toxicology. Sep 13-16; Vienna, Austria; eurotox.com
ESCV 2026 – 28th Annual Meeting of the European
Society of Clinical Virology. Sep 16-19; Porto, Portugal; escv2026.org
NFFK 2026 – Nordic Congress in Clinical Biochemistry. Sep 15-18; Aarhus, Denmark; nfkk.org
OCTOBER
CAP26 – Annual Meeting of the College of American Pathologists. Oct 3-6; Las Vegas, NV, USA; cap.org
ECC 2026 – 46th European Congress of Cytology. Oct 4-7; Antwerp, Belgium; cytology2026.eu
COLABIOCLI 2026 – 27th Latin American Congress of Clinical Biochemistry. Oct 7-11; Santa Cruz, Bolivia; colabiocli.com
MASCL 2026 – Congress of the Association for Mass Spectrometry & Advances in Clinical Lab. Oct 4-9; Montreal, Canada; msacl.org
WHX Labs Cape Town 2026 (formerly Medlab Africa). Oct 13-15; Cape Town, South Africa; worldhealthexpo.com
IFCC WorldLab – 27th International Congress of Clinical Chemistry and Laboratory Medicine. Oct 25-29; New Delhi, India; ifccnewdelhi2026.org
PREMIER MULTIMEDIA PLATFORM SERVING THE WORLD’S CLINICAL LABORATORY COMMUNITY
HIT Testing in Minutes.
The on-demand solution that saves more than time. Fast, accurate HIT antibody detection. Prompt detection of HIT antibodies is critical to selection of the most appropriate therapy. Only Werfen provides a fully automated HIT assay on Hemostasis testing systems, ready-to-use, 24 hours/day, 7 days/week. Complete HIT testing solutions—now on-demand for ACL TOP® testing systems. For more information, contact your local Werfen representative. werfen.com
